The US Food and Drug Administration (FDA) has expanded the indication for Pfizer’s respiratory syncytial virus (RSV) vaccine ...

The vaccine, called Abrysvo, has been approved for the prevention of lower respiratory tract diseases, such as pneumonia and bronchitis, caused by respiratory syncytial virus, or RSV, in people ...

Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower respiratory tract disease ...

Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals ...

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at ...

Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been ...

Between July and September, Abrysvo brought Pfizer $356 million in sales globally, compared to last year’s total of $375 million, according to third quarter earnings Pfizer reported Tuesday.

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the ...

Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved ...

(RTTNews) - Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration approved ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F or RSVpreF vaccine ...